Tasso has partnered with women’s healthcare company SheMed to offer at-home blood testing for weight loss treatments in the UK.
This collaboration aims to personalise glucagon-like peptide-1 (GLP-1) therapies by utilising the Tasso+ blood collection device, enabling completion of comprehensive lab screenings before starting these treatments.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The Tasso+ device, a lancet that collects whole liquid blood samples, is compatible with multiple standard collection tubes and has received US Food and Drug Administration (FDA) Class II Lancet 510(k) clearance.
Tasso’s virtually painless device is said to streamline blood sample collection to a brief and simple process, negating the need to visit a clinic.
Tasso co-founder and CEO Ben Casavant said: “Simplifying blood collection and expanding patient access to essential health data is at the core of our mission at Tasso.
“Our UK collaboration with SheMed is a powerful example of how patient-centric innovation can close long-standing gaps in care and give individuals more control over their health.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataSheMed’s care model is centred around this blood test, revealing essential health markers such as diabetes risk, liver function, thyroid activity and cardiovascular health.
Notably, 99% of individuals display at least one out-of-range result at the time of initial screenings.
These insights enable the care team of SheMed to identify early health issues, tailor every treatment plan, monitor patient progress, and ensure the safe administration of GLP-1 therapy.
SheMed CEO Olivia Ferro said: “At SheMed, our mission is to empower women to take control of their health through safe, accessible, and personalised treatment. Tasso gives our customers access to high-quality at-home blood testing, allowing us to deliver care that meets women where they are.”
In 2023, Tasso secured CE mark certification for its TassoOne Plus high-volume liquid blood collection device.
